Global Diabetic Retinopathy Drug Forecast and Market Analysis to 2029
ResearchAndMarkets.com s offering. Currently, only severe forms of diabetic retinopathy such as PDR and severe NPDR are managed with pharmacotherapy. The standard of care for DME and RVO are anti-angiogenic agents which inhibit vascular endothelial growth factor (VEGF).
The most frequently used anti-VEGF drugs are Roche/Genentech s humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regeneron s fusion protein Eylea (aflibercept). Angiotensin converting enzyme (ACE) inhibitors can be used to treat patients with comorbid hypertension and diabetic retinopathy, while corticosteroids Alimera s Iluvien (fluocinolone acetonide), Allergan s Ozurdex (dexamethasone), and MaQaid (triamcinolone acetonide) can be used to treat people with RVO.